Thrombotic Risk of Targeted Therapies in Breast Cancer: A Real-World Cohort Study
Abstract Purpose Targeted therapies for breast cancer, including CDK4/6, PARP, mTOR, and PI3K inhibitors, have raised concerns regarding thrombosis risk, but real-world data comparing these agents remain limited. We investigated thrombosis incidence and risk factors in a large national cohort of breast cancer patients....